Novocure
NVCR
14.66
-0.31
-2.07%
Novocure
US · NVCR
#2889 by market cap
Listed 2015
14.66
-0.31
-2.07%
Live - 5344 symbols - heartbeat 135s ago
· 2026-10-08 08:24
Pre-market
14.28
-2.59%
After-hours
14.66
0.00%
Overnight
14.65
-0.07%
- Market cap
- 1.71B
- P/E (TTM)i
- -11.28
- P/Bi
- 5.05
- EPSi
- -1.22
- Div yieldi
- 0.00%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on NVCR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.7 percentage points.
Institutional ownership
- Held by institutions
- 90.76% -0.73pp
- Institutions
- 267 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund60.79%
Hedge Fund16.44%
Public Company9.31%
Individual/Insider8.68%
Private Company1.73%
Government Pension Fund1.53%
Insurance Company0.75%
VC/PE Fund0.12%
Other0.56%
Top holders as of 2026-06-30
FMR
14.92% · 17.37M sh
BlackRock
11.52% · 13.41M sh
Soleus Capital Management, L.P.
8.51% · 9.91M sh
Hansjoerg Wyss
6.99% · 8.14M sh
Vanguard Portfolio Management, LLC
5.39% · 6.27M sh
Vanguard Capital Management, LLC
4.86% · 5.66M sh
Morgan Stanley
3.81% · 4.43M sh
State Street Global Advisors
2.46% · 2.87M sh
Geode Capital Management, LLC
2.40% · 2.80M sh
Wells Fargo & Company
2.17% · 2.53M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Hansjoerg Wyss | Former Director | 6.99% |
| William Doyle | Executive Chairperson | 0.46% |
| Asaf Danziger | Chief Executive Officer | 0.19% |
| William Vernon | Lead Independent Director | 0.17% |
| Uri Weinberg | Chief Innovation Officer | 0.13% |
| Frank Leonard | President of CNS Cancers U.S. | 0.13% |
| Ashley Cordova | Chief Financial Officer | 0.11% |
| Barak Ben-Arye | General Counsel | 0.11% |
| Michael Puri | Chief Human Resources Officer | 0.08% |
| Kinyip Leung | Independent Director | 0.08% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-29 | Asaf Danziger | Chief Executive Officer | Other Acquisition | +268 | $11.15 |
| 2026-06-29 | Frank Leonard | President of CNS Cancers U.S. | Other Acquisition | +1,905 | $11.15 |
| 2026-06-29 | Michael Puri | Chief Human Resources Officer | Other Acquisition | +1,905 | $11.15 |
| 2026-06-29 | Barak Ben-Arye | General Counsel | Other Acquisition | +1,299 | $11.15 |
| 2026-06-03 | Frank Leonard | President of CNS Cancers U.S. | Open Market Disposition | -34,273 | $17.93 |
| 2026-06-02 | Jeryl Hilleman | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Jeryl Hilleman | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | David Hung | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | David Hung | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Timothy Scannell | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Timothy Scannell | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Kinyip Leung | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Kinyip Leung | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | William Vernon | Lead Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | William Vernon | Lead Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Martin Madden | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Martin Madden | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Kristin Stafford | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Kristin Stafford | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Allyson Ocean | Independent Director | Other Acquisition | +11,610 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:24:22 · For reference only, not investment advice and not tailored to your situation.